Table 1.
Demographic, clinical characteristics and current prophylactic treatment of the 12 patients with the CACNA1A-p.Thr501Met mutation
| Sex | Headache types IHS criteria | Age | Age of onset (years) | Attacks per month | Duration (hours) | Triggers | Comorbidities | Prophylactic Treatment | |
|---|---|---|---|---|---|---|---|---|---|
| I-1 | F | HM | 76 | 24 | 3 | 0,5–4 | Stress | breast cancer, DM 2 | – |
| I-2 | F | HM | 63 | 18 | 2 | 3–700 | Pregnancy | DM 2, AH, panic disorder | – |
| I-3 | F | HM | 75 | 15 | 3 | 0,5–168 | Menstruations | major depressive disorder, DM 2 | Amitriptyline |
| I-4 | M | HM | 68 | 12 | 1 | 4–96 | Mild head trauma | AH, DM 2 | – |
| I-5 | M | HM | 71 | 6 | 0 | 3–168 | Stress, bright ligths | AH, DM 2, COPD | Acetazolamide + Lamotrigine |
| I-6 | M | HM | 66 | 6 | 2 | 3–168 | – | DM 2, hepatitis B, hiatal hernia | Lamotrigine |
| II-1 | M | ETTH | 45 | 15 | 0 | 1–48 | – | – | – |
| II-2 | F | MO | 29 | 20 | 1 | 0,5–6 | Stress, sleep | – | – |
| II-3 | F | HM | 24 | 14 | 1 | 12–72 | Sleep deprivation, physical exertion | – | – |
| II-4 | F | HM | 31 | 16 | 3 | 0,5–48 | Menstruations | – | – |
| II-5 | M | HM | 35 | 15 | 2 | 0,5–48 | – | thrombophilia | – |
| II-6 | F | HM | 22 | 12 | 3 | 1–72 | Alcohol intake, menstruations | – | – |
Abbreviations: IHS criteria, International Headache Society criteria; HM, hemiplegic migraine; ETTH episodic tension type headache; MO migraine without aura; DM 2 diabetes mellitus type 2; AH arterial hypertension; COPD Chronic Obstructive Pulmonary Disease